<DOC>
	<DOCNO>NCT02259309</DOCNO>
	<brief_summary>The present study design address null hypothesis difference local systemic immunomodulatory effect buccally vaginally administer misoprostol healthy , reproductive-age woman .</brief_summary>
	<brief_title>Immune Modulation Misoprostol</brief_title>
	<detailed_description />
	<mesh_term>Misoprostol</mesh_term>
	<criteria>Healthy woman 1845 year age Negative result urine pregnancy test screen prior administration study drug Normal , regularly occur menses ( 2535 day cycle ) Use hormonal contraception ( current past 3 month ) Use nonsteroidal antiinflammatory drug ( NSAIDs ) aspirin within two week prior enrollment plan use medication study period Allergy prostaglandins Previous cervical cancer Partial complete cervical excision Previous hysterectomy Immunosuppression : either pharmacological due comorbidities Diabetes mellitus Autoimmune disease History lymphoma leukemia Sexually transmit infection ( selfreport ) previous 1 year Bacterial Vaginosis Candidiasis ( current past 3 month )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>misoprostol</keyword>
	<keyword>mucosal</keyword>
	<keyword>cervical</keyword>
	<keyword>immune</keyword>
	<keyword>buccal</keyword>
	<keyword>vaginal</keyword>
</DOC>